ECM Partners and Metric Capital Partners have entered into an agreement to sell their majority stake in FAMAR, the established provider of pharmaceutical development and manufacturing services (CDMO) in MidEuropa.

According to a statement, Mid Europa, a leading private equity investor in Europe, has raised and managed more than €6 billion of capital over its 25-year history. Existing shareholders will retain stakes in FAMAR, confirming their long-term commitment and confidence in the company and its prospects.
FAMAR is a trusted partner to an expanded client base of leading blue-chip pharmaceutical companies, with operations in more than 80 international markets. 

MidEuropa, a leading private equity investor in Europe, has raised and managed more than €6 billion of capital over its 25-year history, according to a press release. Existing shareholders will retain stakes in FAMAR, confirming their long-term commitment and confidence in the company and its prospects. 

FAMAR is a trusted partner to an expanded client base of leading blue-chip pharmaceutical companies, with operations in more than 80 international markets.

The company offers the full range of CDMO value chain services with expanded production capabilities in multiple dosage forms, including sterile, solid, and semi-solid formulations, as well as R&D services. FAMAR has six production sites in southern Europe and two R&D centers, where it employs approximately 1,900 people. 

Konstantinos Reggis, CEO of FAMAR, said: "I would like to thank ECM and Metric for their cooperation over the past four years. Their investment in the company and their support and guidance have been instrumental in making FAMAR a leading force in the CDMO market in Europe. We are excited to partner with MidEuropa to continue to expand to make FAMAR a leading CDMO service platform globally, contributing to the health and well-being of millions of patients around the world." 

Peter Prock, current Chairman of the Board of Directors of FAMAR, said: "I am particularly pleased to see FAMAR open a new chapter as part of their growth path. I look forward to supporting their management team and MidEuropa in their journey to enter new markets and continue to offer their services to their customers as well as to a wider community." 

Savvas Liasis, Chairman of the Board of Directors of ECM, said: "What we saw in FAMAR when we decided to join their shareholding in 2020 was the character of a business that operates to high quality standards and maintains a long tradition of customer service in the pharmaceutical industry. Through extensive efforts, we have been able to expand their portfolio and drive growth by implementing investments with a particular focus on R&D. Today, FAMAR is their leading CDMO with world-class capabilities and service quality. I am confident that the company will continue to thrive under their MidEuropa leadership. We look forward to continuing to support their talented FAMAR management team in their next phase of growth." 

John Sinik, Managing Partner of Metric Capital Partners, said: "We are very pleased to announce the sale of FAMAR to MidEuropa. We extend our sincere congratulations to their management team for their significant achievements over the past four years, during which FAMAR has grown into a leading CDMO in Europe. We are confident that the company, with the support of MidEuropa, will continue to grow and expand into exciting new areas."